 |
Eric J. Small, MD
Recent Publications |
Publications – 2009 |
 |
Fong, L., S.S. Kwek, S. O'Brien, B.
Kavanagh, D.G. McNeel, V. Weinberg, A.M. Lin, J. Rosenberg,
C.J. Ryan, B.I. Rini, and E.J. Small, Potentiating endogenous
antitumor immunity to prostate cancer through combination
immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res,
2009. 69(2): p. 609-15. |
|
Montie, J.E., P.E. Clark, M.A. Eisenberger,
R. El-Galley, R.E. Greenberg, H.W. Herr, G.R. Hudes, D.A.
Kuban, T.M. Kuzel, P.H. Lange, S.M. Lele, J. Michalski, A.
Patterson, K.S. Pohar, J.P. Richie, W.J. Sexton, W.U. Shipley,
E.J. Small, D.L. Trump, P.J. Walther, and T.G. Wilson, Bladder
cancer. J Natl Compr Canc Netw, 2009. 7(1): p. 8-39. |
|
Philips, G.K., S. Halabi, B.L. Sanford,
D. Bajorin, and E.J. Small, A phase II trial of cisplatin
(C), gemcitabine (G) and gefitinib for advanced urothelial
tract carcinoma: results of Cancer and Leukemia Group B (CALGB)
90102. Ann Oncol, 2009. |
| |
Publications – 2008 |
|
Choueiri, T.K., S.A. Vaziri, E. Jaeger,
P. Elson, L. Wood, I.P. Bhalla, E.J. Small, V. Weinberg,
N. Sein, J. Simko, A.R. Golshayan, L. Sercia, M. Zhou, F.M.
Waldman, B.I. Rini, R.M. Bukowski, and R. Ganapathi, von
Hippel-Lindau gene status and response to vascular endothelial
growth factor targeted therapy for metastatic clear cell
renal cell carcinoma. J Urol, 2008. 180(3): p. 860-5; discussion
865-6. |
|
D'Amico, A.V., S. Halabi, C. Tempany,
D. Titelbaum, G.K. Philips, M. Loffredo, E. McMahon, B. Sanford,
N.J. Vogelzang, and E.J. Small, Tumor volume changes on 1.5
tesla endorectal MRI during neoadjuvant androgen suppression
therapy for higher-risk prostate cancer and recurrence in
men treated using radiation therapy results of the phase
II CALGB 9682 study. Int J Radiat Oncol Biol Phys, 2008.
71(1): p. 9-15. |
|
D'Amico, A.V., S. Halabi, R. Vollmer,
M. Loffredo, E. McMahon, B. Sanford, L. Archer, N.J. Vogelzang,
E.J. Small, and P.W. Kantoff, p53 Protein Expression Status
and Recurrence in Men Treated with Radiation and Androgen
Suppression Therapy for Higher-Risk Prostate Cancer: A Prospective
Phase II Cancer and Leukemia Group B Study (CALGB 9682).
Urology, 2008. |
|
Dawson, N.A., S. Halabi, S.S. Ou, D.D.
Biggs, A. Kessinger, N. Vogelzang, G.H. Clamon, D.M. Nanus,
W.K. Kelly, and E.J. Small, A phase II study of estramustine,
docetaxel, and exisulind in patients with hormone- refractory
prostate cancer: results of cancer and leukemia group B trial
90004. Clin Genitourin Cancer, 2008. 6(2): p. 110-6. |
|
Fong, L. and E.J. Small, Anti-cytotoxic
T-lymphocyte antigen-4 antibody: the first in an emerging
class of immunomodulatory antibodies for cancer treatment.
J Clin Oncol, 2008. 26(32): p. 5275-83. |
|
Halabi, S., N.J. Vogelzang, A.B. Kornblith,
S.S. Ou, P.W. Kantoff, N.A. Dawson, and E.J. Small, Pain
predicts overall survival in men with metastatic castration-refractory
prostate cancer. J Clin Oncol, 2008. 26(15): p. 2544-9. |
|
Harzstark, A.L. and E.J. Small, Sipuleucel-T
for the treatment of prostate cancer. Drugs Today (Barc),
2008. 44(4): p. 271-8. |
|
Higano, C.S., J.M. Corman, D.C. Smith,
A.S. Centeno, C.P. Steidle, M. Gittleman, J.W. Simons, N.
Sacks, J. Aimi, and E.J. Small, Phase 1/2 dose-escalation
study of a GM-CSF-secreting, allogeneic, cellular immunotherapy
for metastatic hormone-refractory prostate cancer. Cancer,
2008. 113(5): p. 975-84. |
|
Hurwitz, M.D., S. Halabi, S.S. Ou,
L.S. McGinnis, M.R. Keuttel, S.J. Dibiase, and E.J. Small,
Combination external beam radiation and brachytherapy boost
with androgen suppression for treatment of intermediate-risk
prostate cancer: an initial report of CALGB 99809. Int J
Radiat Oncol Biol Phys, 2008. 72(3): p. 814-9. |
|
Kavanagh, B., S. O'Brien, D. Lee, Y.
Hou, V. Weinberg, B. Rini, J.P. Allison, E.J. Small, and
L. Fong, CTLA4 blockade expands FoxP3+ regulatory and activated
effector CD4+ T cells in a dose-dependent fashion. Blood,
2008. 112(4): p. 1175-83. |
|
Kelly, W.K., S. Halabi, A. Elfiky,
S.S. Ou, J. Bogart, M. Zelefsky, and E.
Small, Multicenter
phase 2 study of neoadjuvant paclitaxel, estramustine phosphate,
and carboplatin plus androgen deprivation before radiation
therapy in patients with unfavorable-risk localized prostate
cancer: results of Cancer and Leukemia Group B 99811. Cancer,
2008. 113(11): p. 3137-45. |
|
Lin, A.M. and E.J. Small, Prostate
cancer update: 2007. Curr Opin Oncol, 2008. 20(3): p. 294-9. |
|
Philips, G.K., S. Halabi, B.L. Sanford, D. Bajorin, and
E.J. Small, A phase II trial of cisplatin, fixed dose-rate
gemcitabine and gefitinib for advanced urothelial tract carcinoma:
results of the Cancer and Leukaemia Group B 90102. BJU Int,
2008. 101(1): p. 20-5. |
|
Rini, B.I., S. Halabi, J.E. Rosenberg,
W.M. Stadler, D.A. Vaena, S.S. Ou, L. Archer, J.N. Atkins,
J. Picus, P. Czaykowski, J. Dutcher, and E.J. Small, Bevacizumab
plus interferon alfa compared with interferon alfa monotherapy
in patients with metastatic renal cell carcinoma: CALGB 90206.
J Clin Oncol, 2008. 26(33): p. 5422-8. |
|
Rosenberg, J.E., S. Halabi, B.L. Sanford, A.L. Himelstein,
J.N. Atkins, R.J. Hohl, F. Millard, D.F. Bajorin, and E.J.
Small, Phase II study of bortezomib in patients with previously
treated advanced urothelial tract transitional cell carcinoma:
CALGB 90207. Ann Oncol, 2008. |
|
Ryan, C.J., A.H. Harzstark, J. Rosenberg,
A. Lin, C. Claros, I.D. Goldfine, J.F. Kerner, E.J. Small,
and J.F. Youngren, A pilot dose-escalation study of the
effects of nordihydroguareacetic acid on hormone and prostate
specific antigen levels in patients with relapsed prostate
cancer. BJU Int, 2008. 101(4): p. 436-9. |
|
Ryan, C.J., A.H. Harzstark, J. Rosenberg, A. Lin, C. Claros,
I.D. Goldfine, J.F. Kerner, and E.J. Small, A pilot dose-escalation
study of the effects of nordihydroguareacetic acid on hormone
and prostate specific antigen levels in patients with relapsed
prostate cancer. BJU Int, 2008. 101(4): p. 436-9. |
|
Scher, H.I., S. Halabi, I. Tannock, M. Morris, C.N. Sternberg,
M.A. Carducci, M.A. Eisenberger, C. Higano, G.J. Bubley,
R. Dreicer, D. Petrylak, P. Kantoff, E. Basch, W.K. Kelly,
W.D. Figg, E.J. Small, T.M. Beer, G. Wilding, A. Martin,
and M. Hussain, Design and end points of clinical trials
for patients with progressive prostate cancer and castrate
levels of testosterone: recommendations of the prostate cancer
clinical trials working group. J Clin Oncol, 2008. 26(7):
p. 1148-59. |
|
Urba, W.J., J. Nemunaitis, F. Marshall,
D.C. Smith, K.M. Hege, J. Ma, M. Nguyen, and E.J. Small,
Treatment of biochemical recurrence of prostate cancer with
granulocyte-macrophage colony-stimulating factor secreting,
allogeneic, cellular immunotherapy. J Urol, 2008. 180(5):
p. 2011-7; discussion 2017-8. |
| |
Publications – 2007 |
|
D'Amico, A.V., S. Halabi, C. Tempany, D.
Titelbaum, G.K. Philips, M. Loffredo, E. McMahon, B. Sanford,
N.J. Vogelzang, and E.J. Small, Tumor Volume Changes on 1.5
Tesla Endorectal Mri During Neoadjuvant Androgen Suppression
Therapy for Higher-Risk Prostate Cancer and Recurrence in
Men Treated Using Radiation Therapy Results of the Phase
Ii Calgb 9682 Study. Int J Radiat Oncol Biol Phys, 2007. |
|
Fong, L. and E.J. Small, Immunotherapy
for prostate cancer. Curr Oncol Rep, 2007. 9(3): p. 226-33. |
|
Garcia, J.A., J.E. Rosenberg, V. Weinberg,
J. Scott, M. Frohlich, J.W. Park, and E.J. Small, Evaluation
and significance of circulating epithelial cells in patients
with hormone-refractory prostate cancer. BJU Int, 2007. 99(3):
p. 519-24. |
|
Halabi, S., S.S. Ou, N.J. Vogelzang, and
E.J. Small, Inverse correlation between body mass index and
clinical outcomes in men with advanced castration-recurrent
prostate cancer. Cancer, 2007. 110(7): p. 1478-84. |
|
Halabi, S., N.J. Vogelzang, S.S. Ou, and
E.J. Small, The impact of prior radical prostatectomy in
men with metastatic castration recurrent prostate cancer:
a pooled analysis of 9 Cancer and Leukemia Group B Trials.
J Urol, 2007. 177(2): p. 531-4. |
|
Harzstark, A.L. and E.J. Small, Immunotherapy
for prostate cancer using antigen-loaded antigen-presenting
cells: APC8015 (Provenge). Expert Opin Biol Ther, 2007. 7(8):
p. 1275-80. |
|
Hsieh, A.C., E.J. Small, and C.J. Ryan,
Androgen-response elements in hormone-refractory prostate
cancer: implications for treatment development. Lancet Oncol,
2007. 8(10): p. 933-9. |
|
Lin, A.M., B.I. Rini, M.K. Derynck, V. Weinberg, M. Park, C.J. Ryan, J.E.
Rosenberg, G. Bubley, and E.J. Small, A phase I trial of docetaxel/estramustine/imatinib
in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer,
2007. 5(5): p. 323-8. |
|
Lin, A.M., C.J. Ryan, and E.J. Small, Intermittent
chemotherapy for metastatic hormone refractory prostate cancer.
Crit Rev Oncol Hematol, 2007. 61(3): p. 243-54. |
|
Lin, A.M. and E.J. Small, Prostate cancer
update: 2006. Curr Opin Oncol, 2007. 19(3): p. 229-33. |
|
Rosenberg, J.E., V.K. Weinberg, W.K. Kelly,
D. Michaelson, M.H. Hussain, G. Wilding, M. Gross, D. Hutcheon,
and E.J. Small, Activity of second-line chemotherapy in docetaxel-refractory
hormone-refractory prostate cancer patients : randomized
phase 2 study of ixabepilone or mitoxantrone and prednisone.
Cancer, 2007. 110(3): p. 556-63. |
|
Ryan, C.J., S. Halabi, S.S. Ou, N.J. Vogelzang,
P. Kantoff, and E.J. Small, Adrenal androgen levels as predictors
of outcome in prostate cancer patients treated with ketoconazole
plus antiandrogen withdrawal: results from a cancer and leukemia
group B study. Clin Cancer Res, 2007. 13(7): p. 2030-7. |
|
Ryan, C.J., C.M. Haqq, J. Simko, D.F. Nonaka,
J.M. Chan, V. Weinberg, E.J. Small, and I.D. Goldfine, Expression
of insulin-like growth factor-1 receptor in local and metastatic
prostate cancer. Urol Oncol, 2007. 25(2): p. 134-40. |
|
Ryan, C.J., W.M. Stadler, B. Roth, D. Hutcheon,
S. Conry, T. Puchalski, C. Morris, and E.J. Small, Phase
I dose escalation and pharmacokinetic study of AZD2171, an
inhibitor of the vascular endothelial growth factor receptor
tyrosine kinase, in patients with hormone refractory prostate
cancer (HRPC). Invest New Drugs, 2007. |
|
Ryan, C.J., V. Weinberg, J. Rosenberg,
L. Fong, A. Lin, J. Kim, and E.J. Small, Phase II study of
ketoconazole plus granulocyte-macrophage colony-stimulating
factor for prostate cancer: effect of extent of disease on
outcome. J Urol, 2007. 178(6): p. 2372-6; discussion 2377. |
|
Small, E.J., J. Fontana, N. Tannir, R.S.
DiPaola, G. Wilding, M. Rubin, R.B. Iacona, and F.F. Kabbinavar,
A phase II trial of gefitinib in patients with non-metastatic
hormone-refractory prostate cancer. BJU Int, 2007. 100(4):
p. 765-9. |
|
Small, E.J., N. Sacks, J. Nemunaitis, W.J.
Urba, E. Dula, A.S. Centeno, W.G. Nelson, D. Ando, C. Howard,
F. Borellini, M. Nguyen, K. Hege, and J.W. Simons, Granulocyte
macrophage colony-stimulating factor--secreting allogeneic
cellular immunotherapy for hormone-refractory prostate cancer.
Clin Cancer Res, 2007. 13(13): p. 3883-91. |
|
Small, E.J., N.S. Tchekmedyian, B.I. Rini,
L. Fong, I. Lowy, and J.P. Allison, A pilot trial of CTLA-4
blockade with human anti-CTLA-4 in patients with hormone-refractory
prostate cancer. Clin Cancer Res, 2007. 13(6): p. 1810-5. |
| |
return
to top
|
|
|
|
|
|
